ProShare Advisors
MLYS icon

ProShare Advisors’s Mineralys Therapeutics MLYS Stock Holding History

ProShare Advisors’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$283K Sell
10,459
-1,581
-13% -$46.4K ﹤0.01% 1371
2025
Q4 		$437K Buy
12,040
+2,985
+33% +$120K ﹤0.01% 1208
2025
Q3 		$343K Sell
9,055
-1,402
-13% -$30.3K ﹤0.01% 1331
2025
Q2 		$141K Buy
+10,457
New +$152K ﹤0.01% 1802
2025
Q1 		– Sell
-10,405
Closed -$128K – 2189
2024
Q4 		$128K Buy
+10,405
New +$136K ﹤0.01% 2014

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

ProShare Advisors's MLYS Position: Q1 2026 in Review

ProShare Advisors reduced its Mineralys Therapeutics (MLYS) stake by 13% in Q1 2026, selling an estimated $46.4K and leaving 10,459 shares worth $283K. The position accounts for ﹤0.01% of the portfolio, ranked #1371.

ProShare Advisors first reported a position in MLYS in Q4 2024 and has held it in 5 quarters since. The position peaked at $437K in Q4 2025. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • ProShare Advisors held 10,459 shares of Mineralys Therapeutics worth $283K as of Q1 2026.
  • ProShare Advisors sold 1,581 Mineralys Therapeutics shares in Q1 2026, an estimated $46.4K.
  • Mineralys Therapeutics made up ﹤0.01% of ProShare Advisors's portfolio in Q1 2026, its #1371 holding.
  • ProShare Advisors first reported a position in Mineralys Therapeutics in Q4 2024 and has held it in 5 quarters since.
  • ProShare Advisors's Mineralys Therapeutics position peaked at $437K in Q4 2025.
  • 214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on ProShare Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.